Stefano Nicole
Vicenza, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study.
Journal: The Journal of antimicrobial chemotherapy
Published: May 14, 2025
Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy.
Journal: The Journal of antimicrobial chemotherapy
Published: July 31, 2021
Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients.
Journal: Infectious diseases (London, England)
Published: May 14, 2019
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
Journal: International journal of STD & AIDS
Published: April 20, 2019
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
Journal: The new microbiologica
Published: October 13, 2018
Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: August 23, 2018
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Journal: International journal of antimicrobial agents
Published: June 18, 2018
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials.
Journal: The Journal of antimicrobial chemotherapy
Published: April 03, 2018
Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life.
Journal: International journal of STD & AIDS
Published: January 12, 2018
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Journal: Infectious diseases (London, England)
Published: December 07, 2017
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients.
Journal: HIV medicine
Published: May 16, 2017
Last Updated: 09/26/2026